Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998–2003
| Autor: | Patrick S. Sullivan, Anne Schuchat, Mitchell I. Wolfe, Eyasu H. Teshale, Brendan Flannery, Christina Phares, Debra L. Hanson |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Endpoint Determination HIV Infections medicine.disease_cause Cohort Studies Pneumococcal Vaccines Young Adult Acquired immunodeficiency syndrome (AIDS) Antiretroviral Therapy Highly Active Internal medicine Streptococcus pneumoniae medicine Humans Longitudinal Studies Models Statistical General Veterinary General Immunology and Microbiology business.industry Public Health Environmental and Occupational Health Middle Aged Pneumonia Pneumococcal Viral Load medicine.disease Pneumococcal polysaccharide vaccine United States CD4 Lymphocyte Count Vaccination Pneumonia Infectious Diseases Socioeconomic Factors Pneumococcal vaccine Immunology Molecular Medicine Female Viral disease business Viral load Follow-Up Studies |
| Zdroj: | Vaccine. 26:5830-5834 |
| ISSN: | 0264-410X |
| DOI: | 10.1016/j.vaccine.2008.08.032 |
| Popis: | Pneumococcal polysaccharide vaccine (PPV-23) has been recommended for HIV-infected adults. We investigated factors that could influence PPV-23 effectiveness against all-cause pneumonia in a longitudinal cohort of 23,255 HIV-infected adults receiving care during 1998--2003. Patients who received PPV-23 had a lower rate of pneumonia (IRR = 0.8; 95% CI: 0.8-0.9) than patients who had never been vaccinated, independent of recent CD4 count, HIV viral load, antiretroviral therapy, and history of pneumonia. However, PPV-23 provided no benefit when patients were vaccinated at HIV viral load > 100,000 copies/ml, irrespective of CD4 count at vaccination. Receipt of PPV-23 was associated with lower incidence of all-cause pneumonia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect